AEMD Latest Report

Financial Performance Review

Based on the provided financial data, Aethlon Medical's revenue in December 2024 was -RMB1814747, a 49.12% improvement from -RMB3567088 in 2023. Although the revenue is still negative, the decrease in the decline indicates improvement in the company's revenue.

Key Financial Data

1. Revenue Improvement: Revenue improved from -RMB3567088 in 2023 to -RMB1814747 in 2024, indicating an improvement in market sales performance or customer base.

2. Reduced Marketing and Management Expenses: Marketing, sales, and general management expenses in 2024 were RMB1436870, a significant reduction from RMB2898502 in 2023, indicating the company's success in cost control.

3. Fluctuation in Interest Income: Interest income in 2024 was RMB59964, a decrease from RMB100967 in 2023, which may affect net profit.

4. Reduced Special Items Expenses: Special items expenses in 2024 were RMB377877, a reduction from RMB668586 in 2023, further improving the company's financial situation.

Peer Comparison

1. Industry-wide Analysis: The medical equipment industry is experiencing recovery after the pandemic, with overall revenue rebounding. Companies that can effectively control costs and optimize operations stand out.

2. Peer Evaluation Analysis: Although Aethlon Medical's revenue is still negative, the reduced decline indicates its improvement in market competition. In contrast, other large medical equipment companies may have achieved positive growth, and Aethlon Medical still needs to work on market share and revenue growth.

Summary

In summary, Aethlon Medical, although still facing negative revenue, has significantly improved, showing positive signals of market recovery and management optimization. Future financial performance will depend on its financing capabilities and product development progress.

Opportunities

1. Market Recovery: The overall recovery of the medical equipment industry provides potential revenue growth opportunities for the company.

2. Cost Control: Effective cost control may further improve profitability.

3. Financing Plan: The company is seeking debt and equity financing, which may provide funding support for future product development.

Risks

1. Negative Cash Flow: Continuous negative cash flow may limit the company's operating and development capabilities.

2. Financing Uncertainty: The difficulty of financing may affect the company's research and clinical trial progress, which may affect future revenue.

3. Industry Competition Pressure: Intense competition requires the company to innovate to maintain competitiveness.